186 related articles for article (PubMed ID: 11115550)
1. p53 expression in Wilms' tumor: a possible role as prognostic factor.
Beniers AJ; Efferth T; Füzesi L; Granzen B; Mertens R; Jakse G
Int J Oncol; 2001 Jan; 18(1):133-9. PubMed ID: 11115550
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome.
Lahoti C; Thorner P; Malkin D; Yeger H
Am J Pathol; 1996 May; 148(5):1577-89. PubMed ID: 8623926
[TBL] [Abstract][Full Text] [Related]
3. Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis.
Hsueh C; Wang H; Gonzalez-Crussi F; Lin JN; Hung IJ; Yang CP; Jiang TH
Mod Pathol; 2002 Jun; 15(6):606-10. PubMed ID: 12065773
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of p53 expression in Wilms' tumor in children.
Skotnicka-Klonowicz G; Kobos J; Łoś E; Trejster E; Szymik-Kontorowicz S; Daszkiewicz P
Med Sci Monit; 2001; 7(6):1224-9. PubMed ID: 11687734
[TBL] [Abstract][Full Text] [Related]
5. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor.
Malkin D; Sexsmith E; Yeger H; Williams BR; Coppes MJ
Cancer Res; 1994 Apr; 54(8):2077-9. PubMed ID: 8174107
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical detection of p53 protein expression as a prognostic factor in Wilms tumor.
Jadali F; Sayadpour D; Rakhshan M; Karimi A; Rouzrokh M; Shamsian BS; Shamshiri AR
Iran J Kidney Dis; 2011 Jul; 5(3):149-53. PubMed ID: 21525573
[TBL] [Abstract][Full Text] [Related]
7. Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor.
Basta-Jovanović G; Radonjic V; Stolic I; Nenadovic M; Brasanac D; Jovanovic D; Radojevic-Skodric S
Ren Fail; 2005; 27(1):13-8. PubMed ID: 15717629
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of the drug resistance markers DNA topoisomerase II alpha and glutathione S-transferase-pi in the histological compartments of Wilms' tumors.
Granzen B; Efferth T; Keller U; Beniers AJ; Mertens R; Jakse G; Füzesi L
Anticancer Res; 2001; 21(1B):771-6. PubMed ID: 11299842
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of p53 proteins in Wilms' tumour: a possible association with the histological prognostic parameter of anaplasia.
Cheah PL; Looi LM; Chan LL
Histopathology; 1996 Jan; 28(1):49-54. PubMed ID: 8838120
[TBL] [Abstract][Full Text] [Related]
10. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
11. Mutations of p53 in Wilms' tumors.
Takeuchi S; Bartram CR; Ludwig R; Royer-Pokora B; Schneider S; Imamura J; Koeffler HP
Mod Pathol; 1995 Jun; 8(5):483-7. PubMed ID: 7675765
[TBL] [Abstract][Full Text] [Related]
12. Expression and prognostic value of Wilms' tumor 1 and early growth response 1 proteins in nephroblastoma.
Ghanem MA; Van der Kwast TH; Den Hollander JC; Sudaryo MK; Oomen MH; Noordzij MA; Van den Heuvel MM; Nassef SM; Nijman RM; Van Steenbrugge GJ
Clin Cancer Res; 2000 Nov; 6(11):4265-71. PubMed ID: 11106242
[TBL] [Abstract][Full Text] [Related]
13. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotype, mRNA expression, and gene structure of p53 in Wilms' tumors.
el Bahtimi R; Hazen-Martin DJ; Re GG; Willingham MC; Garvin AJ
Mod Pathol; 1996 Mar; 9(3):238-44. PubMed ID: 8685221
[TBL] [Abstract][Full Text] [Related]
15. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
[TBL] [Abstract][Full Text] [Related]
16. p53 immunopositivity in histologically favorable Wilms tumor is not related to stage at presentation or to biological aggression.
D'Angelo MF; Kausik SJ; Sebo TJ; Rathbun SR; Kramer SA; Husmann DA
J Urol; 2003 May; 169(5):1815-7. PubMed ID: 12686851
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of GLUT1 and its correlation with unfavorable histology and TP53 codon 72 polymorphism in Wilms tumors.
Rakheja D; Khokhar S; Mitui M; Cost NG
Pediatr Dev Pathol; 2012; 15(4):286-92. PubMed ID: 22483234
[TBL] [Abstract][Full Text] [Related]
18. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus.
Jeffers MD; Farquharson MA; Richmond JA; McNicol AM
J Pathol; 1995 Sep; 177(1):65-70. PubMed ID: 7472782
[TBL] [Abstract][Full Text] [Related]
19. Nuclear accumulation of beta-catenin protein in Wilms' tumours.
Koesters R; Niggli F; von Knebel Doeberitz M; Stallmach T
J Pathol; 2003 Jan; 199(1):68-76. PubMed ID: 12474228
[TBL] [Abstract][Full Text] [Related]
20. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status.
Tolbert DM; Noffsinger AE; Miller MA; DeVoe GW; Stemmermann GN; Macdonald JS; Fenoglio-Preiser CM
Mod Pathol; 1999 Jan; 12(1):54-60. PubMed ID: 9950163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
